Institutional Confidence Rises as CorMedix Inc. (CRMD) Hits Profitability

CorMedix Inc. (NASDAQ:CRMD) is among the fastest growing small cap stocks to buy. During the first quarter, the Swiss National Bank expanded its position in CorMedix Inc. (NASDAQ:CRMD) as disclosed with the Securities and Exchange Commission. Through the purchase of 117,600 shares of the company’s stock, with a worth of nearly $724,000, the bank now owns 0.17% of the company.

Just as the dawn breaks after the darkest night, CorMedix Inc. (NASDAQ:CRMD) has finally stepped into profitability, and that too quite quickly. Having said that, the quarterly revenue growth (YoY) of the company stands at an impressive 4,829.40%. That’s not it. While the one-year return delivered by the S&P 500 (^GSPC) is reported at 15.53%, the company returned nearly ten times more, a staggering return of approximately 144.32%.

The company’s future looks equally appealing, all thanks to DefenCath’s FDA approval and successful commercialization. The product is unique in itself as it not only brings value to insurance companies but also captures significant market share.

CorMedix Inc. (NASDAQ:CRMD), incorporated in 2006, is a New Jersey-based biopharmaceutical company that provides treatments for serious conditions. With DefenCath as its lead candidate, the company is committed to addressing critical unmet medical needs.

While we acknowledge the potential of CRMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.